KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Non-Current Deferred Tax Liability: 2016-2024

Historic Non-Current Deferred Tax Liability for BeOne Medicines (ONC) over the last 8 years, with Dec 2024 value amounting to $42.0 million.

  • BeOne Medicines' Non-Current Deferred Tax Liability rose 195.36% to $47.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.1 million, marking a year-over-year increase of 195.36%. This contributed to the annual value of $42.0 million for FY2024, which is 108.90% up from last year.
  • Latest data reveals that BeOne Medicines reported Non-Current Deferred Tax Liability of $42.0 million as of FY2024, which was up 108.90% from $20.1 million recorded in FY2023.
  • In the past 5 years, BeOne Medicines' Non-Current Deferred Tax Liability ranged from a high of $42.0 million in FY2024 and a low of $10.8 million during FY2020.
  • Moreover, its 3-year median value for Non-Current Deferred Tax Liability was $24.6 million (2022), whereas its average is $28.9 million.
  • As far as peak fluctuations go, BeOne Medicines' Non-Current Deferred Tax Liability dropped by 18.18% in 2023, and later skyrocketed by 108.90% in 2024.
  • Over the past 5 years, BeOne Medicines' Non-Current Deferred Tax Liability (Yearly) stood at $10.8 million in 2020, then surged by 31.29% to $14.2 million in 2021, then spiked by 73.46% to $24.6 million in 2022, then dropped by 18.18% to $20.1 million in 2023, then skyrocketed by 108.90% to $42.0 million in 2024.